### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

## CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest eve	nt reported)	May 4, 2009	
HENRY	SCHEIN, INC.		
(Exact name of registra	nt as specified ir		
DELAWARE	0-27078 11-3136595		
(State or other jurisdiction of incorporation)	(Commission File	(IRS Employer Identification N	
135 DURYEA ROAD, MELVILLE, NEW YO	RK		11747
(Address of principal executive offi			Code)
Registrant's telephone number, including area code (631) 843-5500			
NOT	APPLICABLE		
(Former name or former addr			
Check the appropriate box below if t simultaneously satisfy the filing ob following provisions (see General In	ligation of the re	egistrant under any	of the
[ ] Written communications pursuant 230.425)	to Rule 425 under	the Securities Act	(17 CFR
[ ] Soliciting material pursuant to 240.14a-12)	Rule 14a-12 under	the Exchange Act (1	L7 CFR
[ ] Pre-commencement communications Act (17 CFR 240.14d-2(b))	pursuant to Rule 1	L4d-2(b) under the E	Exchange
[ ] Pre-commencement communications Act (17 CFR 240.13e-4(c))	pursuant to Rule 1	L3e-4(c) under the E	Exchange

Item 2.02. Results of Operations and Financial Condition.

On May 4, 2009, Henry Schein, Inc. issued a press release reporting the financial results for the three months ended March 28, 2009. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.
- (d) Exhibit 99.1 Press Release dated May 4, 2009.

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By: /s/ Steven Paladino

Steven Paladino

Executive Vice President and Chief Financial Officer

Chief Financial Officer (principal financial and accounting

officer)

May 4, 2009

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release dated May 4, 2009.

Henry Schein, Inc. - 135 Duryea Road - Melville, New York 11747

FOR IMMEDIATE RELEASE

MELVILLE, N.Y. - May 4, 2009 - Henry Schein, Inc. (NASDAQ: HSIC), the largest provider of healthcare products and services to office-based practitioners, today reported financial results for the quarter ended March 28, 2009.

Net sales for the first quarter of 2009 were \$1.5 billion, a decrease of 2.2% compared with the first quarter of 2008. This consists of 5.5% growth in local currencies offset by a 7.7% decline related to foreign currency exchange (see Exhibit A for details of sales growth).

Income from continuing operations attributable to Henry Schein, Inc. for the first quarter of 2009 was \$54.9 million, or \$0.61 per diluted share. These results include restructuring costs of \$4.0 million (or \$0.03 per diluted share, after-tax) related to the completion of the expense reduction program announced in November 2008. Excluding the impact of these restructuring costs, income from continuing operations attributable to Henry Schein, Inc. for the quarter was \$57.6 million, or \$0.64 per diluted share, an increase of 11.9% and 14.3%, respectively, compared with the first quarter of 2008 (see Exhibit B for reconciliation of GAAP net income and EPS to non-GAAP adjusted net income and EPS).

Income from continuing operations for the first quarter of 2008 has been restated for the adoption of FASB Staff Position APB 14-1, which requires the recognition of non-cash interest expense related to convertible debt. The impact of this adoption decreased first quarter 2008 diluted EPS by approximately \$0.01.

"With market conditions largely as we expected during the quarter, we remain committed to managing expenses and delivering growth in diluted EPS from continuing operations," said Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein. "Our operating margin excluding restructuring costs once again expanded, up 77 basis points for the quarter to 6.4%. This is primarily a reflection of effective expense management. We continue to have a very strong balance sheet with \$308 million in cash at quarter-end, and access to capital at favorable terms."

-more-

Dental Group sales of \$597 million declined 2.4%, consisting of a 0.4% decline in local currencies and a 2.0% decline related to foreign currency exchange. The 0.4% decline in local currencies consists of 1.0% growth in Dental consumable merchandise sales and a 5.1% decline in Dental equipment sales and service revenues.

Medical Group sales of \$327 million declined 1.2%, and were negatively impacted by higher sales of private label products, increased sales of generic pharmaceuticals, and manufacturer shortages of certain vaccines.

International Group sales of 524 million declined 3.0%, consisting of 16.2% growth in local currencies and a 19.2% decline related to foreign currency exchange.

"International internal sales growth in local currencies was nearly 6%, reflecting particular strength in Australia and New Zealand, as well as with our European veterinary business," added Mr. Bergman. "We were encouraged by the excellent attendance at the biennial International Dental Show held late in the quarter in Cologne, Germany, which is one of the largest and most important gatherings of dentists from across Europe. Our booth was busy, and equipment orders exceeded those received at the 2007 show."

Technology and Value-Added Services Group sales of \$40 million increased 3.9% during the quarter, consisting of 8.8% growth in local currencies and a 4.9% decline related to foreign currency exchange.

"Our electronic services business was particularly strong during the quarter, up more than 20%, while financial services revenue reflects 3.5% growth in equipment and practice financing," stated Mr. Bergman.

#### Restructuring Costs

The Company recorded \$4.0 million of costs in the first quarter of 2009 for restructuring actions taken to complete the expense reduction program initiated in the fourth quarter of 2008. The program, which resulted in the elimination of approximately 400 positions and the closure of several smaller facilities, is now complete and is expected to provide approximately \$24 to \$27 million in annual pretax cost savings.

#### 2009 EPS Guidance

Henry Schein today affirmed 2009 financial guidance, as follows:

o 2009 diluted EPS attributable to Henry Schein, Inc. is expected to be \$3.11 to \$3.26, representing growth of 7% to 12% compared with restated 2008 results of \$2.92, excluding charges related to the Lehman Brothers bankruptcy as well as restructuring costs. The 2009

2 -moreguidance also excludes the effects of restructuring costs.

o Guidance for 2009 diluted EPS attributable to Henry Schein, Inc. is for current continuing operations including completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any.

#### First Quarter Conference Call Webcast

The Company will hold a conference call to discuss first quarter financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call over the Internet through Henry Schein's Web site at www.henryschein.com. In addition, a replay will be available beginning shortly after the call has ended.

#### About Henry Schein

Henry Schein, a Fortune 500(R) company and a member of the NASDAQ 100(R) Index, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 575,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions.

The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein privatebrand products in stock, as well as more than 100,000 additional products available as special-order items.

Henry Schein also offers a wide range of innovative value-added practice solutions for healthcare professionals, such as ArubA(R), the Company's electronic catalog and ordering system. Its leading practice-management software solutions have an active user base of more than 60,000 practices, including DENTRIX(R), Easy Dental(R), Oasis(R) and EXACT(R) for dental practices, MicroMD(R) for physician practices, and AVImark(R) for animal health clinics.

MicroMD(R) for physician practices, and AVImark(R) for animal health clinics.

Headquartered in Melville, N.Y., Henry Schein employs over 12,500
people and has operations or affiliates in 23 countries. The Company's net sales reached a record \$6.4 billion in 2008. For more information, visit the Henry Schein Web site at www.henryschein.com.

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: decreased customer demand and changes in vendor credit terms; disruptions in financial markets; general economic conditions; competitive factors; changes in the healthcare industry; changes in regulatory requirements that affect us; risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence upon sales personnel and key customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service issues with our third-party shippers; risks from rapid technological change; risks from potential increases in variable interest rates; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation that affect us. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

(TABLES TO FOLLOW)

4 - more -

# HENRY SCHEIN, INC. CONSOLIDATED STATEMENTS OF INCOME (in thousands, except per share data) (unaudited)

		Three Months Ended		
		March 28, 2009		March 29, 2008
Net sales  Cost of sales	\$	1,488,605 1,047,595	\$	1,521,777 1,071,146
Gross profit		441,010		450,631
Operating expenses: Selling, general and administrative		346,080 4,043		365,356
Operating income		90,887 2,801 (6,814)		85,275 3,983 (8,167)
Income from continuing operations before taxes, noncontrolling interest and equity in earnings of affiliates		86,857 (28,922) 1,365		80,708 (27,446) 1,510
Income from continuing operations Loss from discontinued operations, net of tax		59,300 		54,772 (82)
Net income Less: Net income attributable to noncontrolling interests		59,300		54,690
Net income attributable to Henry Schein, Inc	\$		\$	51,440
Amounts attributable to Henry Schein, Inc.: Income from continuing operations	\$	54,851 	\$	51,522 (82)
Net income	\$ ==	54,851	\$ ==	51,440 ======
Earnings per share attributable to Henry Schein, Inc.:				
From continuing operations: Basic		0.62		0.58
Diluted	\$ ==	0.61	\$ ==	0.56 =====
From discontinued operations: Basic	-	0.00	\$	0.00
Diluted	\$	0.00	\$	0.00
From net income: Basic	-	0.62		0.58
Diluted	\$	0.61	\$	0.56
Weighted-average common shares outstanding: Basic		88,731		89,223
Diluted		89,589 =======		92,259

Note: The above prior period amounts have been restated to reflect the effects of discontinued operations, the adoption of FASB Staff Position APB 14-1 related to convertible debt and FAS 160 related to the presentation of noncontrolling interests.

5 - more -

# HENRY SCHEIN, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data)

	March 28, 2009	December 27, 2008	
	(unaudited)		
ASSETS Current assets:			
Cash and cash equivalents	\$ 308,156 677,193 740,947 37,386 176,634	\$ 369,570 734,027 731,654 36,974 193,841	
Total current assets  Property and equipment, net  Goodwill  Other intangibles, net  Investments and other	1,940,316 242,175 899,884 203,163 147,006	2,066,066 247,835 922,952 214,093 148,264	
Total assets	\$ 3,432,544 ========	\$ 3,599,210 =======	
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:    Accounts payable    Bank credit lines    Current maturities of long-term debt    Accrued expenses:     Payroll and related     Taxes     Other  Total current liabilities Long-term debt Deferred income taxes	\$ 426,066 1,911 155,044 106,768 84,304 237,792 	\$ 554,773 4,936 156,405 135,523 69,792 262,236 	
Other liabilities	56, 131	58, 109	
Commitments and contingencies  Stockholders' equity:     Preferred stock, \$.01 par value, 1,000,000 shares authorized,     none outstanding			
90,150,568 outstanding on March 28, 2009 and 89,351,849 outstanding on December 27, 2008	902 729,939 1,236,305 (15,580)	894 725,540 1,181,454 29,721	
Total Henry Schein, Inc. stockholders' equity	1,951,566 70,494	1,937,609 67,780	
Total stockholders' equity	2,022,060	2,005,389	
Total liabilities and stockholders' equity	\$ 3,432,544 =======	\$ 3,599,210 ======	

Note: The above prior period amounts have been restated to reflect the adoption of FASB Staff Position APB 14-1 related to convertible debt and FAS 160 related to the presentation of noncontrolling interests.

# HENRY SCHEIN, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited)

Three Months Ended

	March	28,	Ма	arch 29, 2008
Cash flows from operating activities:				
Net income attributable to Henry Schein, Inc	\$ 5	4,851	\$	51,440
Depreciation and amortization		9,921 1,464		19,438 1,382
Stock-based compensation expense	(	6,067 1,186 5,485) 1,365)		9,260 1,137 (3,809) (1,510)
Net income attributable to noncontrolling interests Other		4,449 1,616		3,250 (426)
Accounts receivable		3,397 1,039)		16,504 (21,087)
Other current assets	`1 (14	2,669 4,859)		2,514 (64,720)
Net cash provided by (used in) operating activities	(2	7 128)		13,373
Cash flows from investing activities:				
Purchases of fixed assets	(1	2,866)		(13,743)
net of cash acquired  Purchases of available-for-sale securities	(1	3,743)		(8,524) (35,925)
Proceeds from sales of available-for-sale securities Net proceeds from (payments for) foreign exchange forward		2,740		847
contract settlements Other	(	283 4,294)		(2,004) (768)
Net cash used in investing activities	(2	7,880)		(60,117)
Cash flows from financing activities:				
Repayments of bank borrowings	(	3,189)		(3,919)
Principal payments for long-term debt	(	1,712)		(973)
Proceeds from issuance of stock upon exercise of stock options		377		7,172
Excess tax benefits related to stock-based compensation	,	180 2,090)		3,429
Other	)	2,090)		(424)
Net cash provided by (used in) financing activities	(	6,434)		5,285
Net change in cash and cash equivalents		1,442)		(41,459)
Effect of exchange rate changes on cash and cash equivalents	( -	´ 28´		(3,095)
Cash and cash equivalents, beginning of period	36	9,570		247,590
Cash and cash equivalents, end of period		8,156	\$	

Note: The above prior period amounts have been restated to reflect the adoption of FASB Staff Position APB 14-1 related to convertible debt and FAS 160 related to the presentation of noncontrolling interests.

Henry Schein, Inc. 2009 First Quarter Sales Growth Rate Summary (unaudited)

Q1 2009 over Q1 2008

Consolidated Dental Medical International Technology Internal Sales Growth 0.5% -3.0% -2.4% 5.8% 8.8% 1.2% 10.4% Acquisitions 5.0% 2.6% 0.0% -----Local Currency Sales Growth 5.5% -0.4% -1.2% 16.2% 8.8% Foreign Currency Exchange 0.0% -7.7% -2.0% -19.2% -4.9% -1.2% -2.2% Total Sales Growth 3.9% -2.4% -3.0% 

> 8 - more -

Henry Schein, Inc. 2009 First Quarter Reconciliation of GAAP results of continuing operations to non-GAAP results of continuing operations (in thousands, except per share data) (unaudited)

	First Quarter		%	
	2009	2008	Growth	
From Continuing Operations				
Net Sales		\$1,521,777	-2.2%	
Operating Income	90,887	85,275	6.6%	
Margin	6.1%	5.6%	50 bp	
Income from Continuing Operations attributable				
to Henry Schein, Inc.	\$ 54,851	\$ 51,522	6.5%	
Diluted EPS from Continuing Operations				
attributable to Henry Schein, Inc.	0.61	0.56		
Net Income attributable to Henry Schein, Inc.		51,440		
Diluted EPS	0.61	U.50	8.9%	
Add: Non-GAAP Adjustments				
Net Sales Operating Income	\$ 4,043			
Income from Continuing Operations attributable	Φ 4,043			
to Henry Schein, Inc.	2,784			
Diluted EPS from Continuing Operations	2,104			
attributable to Henry Schein, Inc.	0.03			
Net Income attributable to Henry Schein, Inc.	2,784			
Diluted EPS	0.03			
Addusted Deville from Outlinein Organica				
Adjusted Results from Continuing Operations				
Net Sales		\$1,521,777	-2.2%	
Operating Income		85,275		
Margin	6.4%	5.6%	77 bp	
Income from Continuing Operations attributable			· ·	
to Henry Schein, Inc.	\$ 57,635	\$ 51,522	11.9%	
Diluted EPS from Continuing Operations				
attributable to Henry Schein, Inc.	0.64	0.56		
Net Income attributable to Henry Schein, Inc.	,	51,440		
Diluted EPS	0.64	0.56	14.3%	

### Note:

Above reflects adjusted results from continuing operations excluding restructuring costs of \$4,043 (\$2,784 after tax and \$.03 per diluted share) recorded in the first quarter of 2009. This non-GAAP comparison is being presented in order to provide a more comparable basis for analysis.

CONTACTS: Investors: Steven Paladino

Executive Vice President and Chief Financial Officer

steven.paladino@henryschein.com

(631) 843-5500

Media: Susan Vassallo

Vice President, Corporate Communications susan.vassallo@henryschein.com

(631) 843-5562

9 ###